HL CORP(SZ:002105) Zheng Quan Zhi Xing·2025-08-22 13:19Core Viewpoint - The legal opinion issued by Guangdong Xinda Law Firm confirms that Shenzhen Xinlong Health Industry Development Co., Ltd. has obtained the necessary approvals for the repurchase and cancellation of certain restricted stocks under its 2023 incentive plan, pending final approval from the shareholders' meeting [1][9]. Group 1: Approval and Authorization - On June 15, 2023, the company held its first extraordinary general meeting of shareholders, which approved the 2023 restricted stock incentive plan and authorized the board of directors to implement the plan [2][3]. - The board is authorized to handle various matters related to the incentive plan, including adjustments to the number and price of restricted stocks in case of stock splits or dividends [3][4]. Group 2: Specifics of the Repurchase - The company plans to repurchase and cancel a total of 1,818,050 shares of restricted stock, which includes 75,000 shares from two departing incentive recipients and 1,743,050 shares that did not meet the release conditions [5][6]. - The repurchase price for the restricted stocks is set at 3.49 yuan per share, adjusted from the previous price of 3.52 yuan [4][5]. Group 3: Performance Targets and Conditions - The incentive plan stipulates that the release of restricted stocks is contingent upon meeting specific performance targets, including a revenue growth rate of no less than 5% for 2024 and 10% for 2025, based on 2022 revenue [7][8]. - The actual performance for the first release period did not meet the targets, leading to the cancellation of the corresponding restricted stocks [9]. Group 4: Legal Compliance - The legal opinion asserts that the repurchase and cancellation of restricted stocks comply with the Company Law, Securities Law, and relevant regulations, but still requires approval from the shareholders' meeting [9][10].